



Republic of the Philippines  
Department of Health  
**FOOD AND DRUG ADMINISTRATION**



FDA ADVISORY  
No. **2021-2459**

13 OCT 2021

TO: THE GENERAL PUBLIC

SUBJECT: Certification of Contraceptive Products in Compliance to the Implementing Rules and Regulations of the Republic Act No. 10354, Also Known as the Responsible Parenthood and Reproductive Health Act of 2012

In compliance with Republic Act No. 10354, also known as “The Responsible Parenthood and Reproductive Health Act of 2012” and its IRR, the Food and Drug Administration (FDA) hereby invites all concerned to submit their petitions and any corresponding evidence on the mechanism of action of the following contraceptive products within ten (10) calendar days from the posting of this Advisory:

Generic Name	Dosage Strength and Form	Brand Name	Marketing Authorization Holder (MAH)
1) Dienogest	2 mg Tablet	Vinca	Embil International Philippines, Inc.
2) Medroxyprogesterone	150 mg/mL Suspension for Injection (IM)	Medroxin	Endure Medical, Inc.

Documents and scientific evidence can be submitted to the Food and Drug Action Center (FDAC), 3<sup>rd</sup> Floor Starmall, Alabang, Muntinlupa on Mondays to Fridays, 8:00 am to 5:00 pm or email to [fdac.letters.cdrr@fda.gov.ph](mailto:fdac.letters.cdrr@fda.gov.ph).



20211012152532

  
**ROLANDO ENRIQUE D. DOMINGO, MD**

Director General

Keywords	Contraceptive drugs and devices, Certification, Abortifacient
Related issuances, laws, directives from other government agencies	Republic Act No. 10354 and its Implementing Rules and Regulations, Supreme Court Resolution on Alliance for the Family Foundation, Inc. et al v. Hon. Janette L. Garin, et al, G.R. No. 217872 and G.R. No. 221866

Civic Drive, Filinvest City, Alabang 1781 Muntinlupa, Philippines

Trunk Line +63 2 857 1900

Website: [www.fda.gov.ph](http://www.fda.gov.ph)

Fax +63 2 807 0751

Email: [info@fda.gov.ph](mailto:info@fda.gov.ph)



Management System  
ISO 9001:2015



www.tuv.com  
ID: 910507386